Sign in
Taking people in NetherlandsPhase 3

Combined LT4 and LT3 treatment for tiredness in autoimmune hypothyroidism

Tests LT4 plus LT3 versus LT4 alone for lasting tiredness in hypothyroidism.

Key facts

Who runs it
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Where
Alkmaar, Almere, Amsterdam, Apeldoorn, Arnhem, Breda, Dirksland, Dordrecht, Eindhoven, Emmen, Geleen, Goes, Groningen, Hardenberg, Hilversum, Nijmegen, Rotterdam, Utrecht, and Venlo, NetherlandsSee the 21 sites
Registry title
T3-4-Hypo trial
Status
Recruiting
Phase
Phase 3
People taking part
600 people, planned
Started
2 Nov 2025
Expected to end
1 Jan 2029
Type of study
Interventional
Record updated
11 July 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with autoimmune hypothyroidism (underactive thyroid) who still feel severely tired while taking LT4 alone. It compares LT4 plus LT3 with LT4 alone.

Age
18 years or older.
Sex
All sexes can join.
Disease stage
Overt or subclinical hypothyroidism. Severe tiredness with a large negative impact on daily life for at least 6 months, based on the patient's own experience.
Earlier treatment
LT4 alone for at least 6 months, at a dose of 75-225 microg and at least 1.2microg/kg. People who had thyroid surgery or radioactive iodine treatment cannot join.
Biomarker or test result
TSH levels within the reference ranges of the test for at least 3 months.

Main reasons for not taking part

  • Thyroid surgery or radioactive iodine treatment.
  • Current or past use of drugs that affect the thyroid, such as amiodarone, immunotherapy, tyrosin kinase inhibitors, interferon or lithium.
  • Heart problems, such as current or past atrial fibrillation, abnormal heart, or certain ECG changes.
  • Pregnancy, breastfeeding or wish to become pregnant within 2 years.
  • Another clear medical or life-event cause for the tiredness, or dementia, or not fluent in Dutch.

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Patients with overt or subclinical hypothyroidism 18 years or older.LT4 monotherapy for at least 6 months.LT4 monotherapy dose of 75-225 microg, with at least a dose of 1.2microg/kg. TSH levels within the assay-specific reference ranges for at least 3 months. Severe tiredness with a large negative impact on daily life for at least 6months, with or without other persisting complaints. This is based on the patient's own experience, without judgment of the treating physician. Sufficiently fluent in Dutch and able to read Dutch

Who cannot take part

  • Thyroid surgery Radioactive iodine treatment Use of thyroid interfering drugs (current/past use of amiodarone, immunotherapy, tyrosin kinase inhibitors, interferon or lithium and current use of oral or iv corticosteroids or dopamine) Current psychiatric disease treated at a "gespecialiseerde GGZ instelling" Clinical diagnosis of dementia Pregnancy, breastfeeding or wish to become pregnant within 2 years Current/past atrial fibrillation Functional or structural abnormal heart (e.g. cardiomyopathy or valve disease) Current conduction disorder on ECG (i.e. Prolonged QRS > 100 ms; or prolonged QTc; QTc women > 460 msec / men > 450 msec) Frequentventricular extrasystole (=doublet, trigeminy, bigeminy or (non-sustained) ventricular tachycardia) in the past or on current ECG Recent acute coronary syndrome or unstable angina pectoris (< 4 weeks) Other obvious medical explanation for tiredness (e.g. end-stage renal disease, anemia, COPD stage IV, cancer, etc.) Other obvious major life event explanation for tiredness (e.g. mourning, loss of job)

Where in Netherlands

  • Noordwest Ziekenhuisgroep StichtingAlkmaar, NetherlandsTaking people
  • Flevoziekenhuis StichtingAlmere, NetherlandsTaking people
  • Academic Medical Center at the University of AmsterdamAmsterdam, NetherlandsTaking people
  • Gelre HospitalsApeldoorn, NetherlandsTaking people
  • Rijnstate Ziekenhuis StichtingArnhem, NetherlandsTaking people
  • Amphia HospitalBreda, NetherlandsTaking people
  • Het Van Weel-Bethesda ZiekenhuisDirksland, NetherlandsTaking people
  • Albert Schweitzer ZiekenhuisDordrecht, NetherlandsTaking people
  • Máxima Medisch CentrumEindhoven, NetherlandsTaking people
  • Treant Ziekenhuiszorg StichtingEmmen, NetherlandsTaking people
  • Zuyderland Medisch Centrum StichtingGeleen, NetherlandsTaking people
  • Admiraal De Ruyter Ziekenhuis B.V.Goes, NetherlandsTaking people
  • Universitair Medisch Centrum GroningenGroningen, NetherlandsTaking people
  • Saxenburgh Medisch CentrumHardenberg, NetherlandsTaking people
  • TergooiziekenhuizenHilversum, NetherlandsTaking people
  • Radboud Universitair Medisch Centrum (Radboudumc)Nijmegen, NetherlandsTaking people
  • Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, NetherlandsTaking people
  • Maasstad Ziekenhuis StichtingRotterdam, NetherlandsTaking people
  • Sint Franciscus Vlietland Groep StichtingRotterdam, NetherlandsTaking people
  • Universitair Medisch Centrum UtrechtUtrecht, NetherlandsTaking people
  • Stichting Viecuri Medisch Centrum voor Noord-LimburgVenlo, NetherlandsTaking people

About the trial

What the trial wants to find out

To investigate the effects of LT4/LT3 combination therapy compared to LT4 monotherapy on tiredness in those patients with autoimmune hypothyroidism and persisting tiredness on LT4 monotherapy, after 1 year of treatment. In case it is confirmed that LT4/LT3 combination therapy reduces tiredness compared to LT4 treatment alone, the primary objective includes investigating simultaneously whether effect sizes are higher in patients with genetic variation in the type 2 deiodinase (DIO2-rs225014) and effect sizes are higher in patients with genetic variation in the monocarboxylate transporter 10 (MCT10-rs17606253).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A national randomized placebo-controlled double-blind multicenter trial of LT4/LT3 combination therapy in patients with autoimmune hypothyroidism: the T3-4-Hypo trial
Plain-language title
Combined LT4 and LT3 treatment for tiredness in autoimmune hypothyroidismGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
11 July 2025